Real-world andexanet alfa utilization and the association between delay in administration due to hospital transfer and all-cause inpatient mortality.

ABSTRACT:

Background

Evaluations of andexanet alfa for the reversal of factor Xa inhibitor-associated bleeding have been small, with cohorts drawn from single/limited sites. Delays in providing anticoagulation reversal due to hospital transfer may result in poorer outcomes.

Objectives

To describe the characteristics and outcomes of andexanet alfa users and evaluate the association between delay in andexanet alfa administration due to transfer from a different acute care hospital and the incidence of all-cause inpatient mortality.

Methods

This was a retrospective study using National Inpatient Sample data. Hospitalizations with procedural codes for andexanet alfa and a billing code for bleeding were included. Descriptive analysis was performed, as was multivariable logistic regr

SUBMITTER: Fan H 

PROVIDER: S-EPMC11889373 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature